ProPhase Labs, Inc. (NASDAQ:PRPH) Shares Bought by Renaissance Technologies LLC

Renaissance Technologies LLC boosted its stake in ProPhase Labs, Inc. (NASDAQ:PRPH) by 33.2% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 286,485 shares of the company’s stock after acquiring an additional 71,375 shares during the period. Renaissance Technologies LLC’s holdings in ProPhase Labs were worth $217,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of PRPH. HighTower Advisors LLC raised its holdings in ProPhase Labs by 32.2% during the fourth quarter. HighTower Advisors LLC now owns 236,781 shares of the company’s stock worth $179,000 after purchasing an additional 57,736 shares in the last quarter. Geode Capital Management LLC grew its holdings in ProPhase Labs by 26.6% in the fourth quarter. Geode Capital Management LLC now owns 203,528 shares of the company’s stock valued at $154,000 after purchasing an additional 42,793 shares during the last quarter. SVB Wealth LLC acquired a new stake in shares of ProPhase Labs in the fourth quarter valued at approximately $36,000. Perritt Capital Management Inc lifted its position in shares of ProPhase Labs by 129.1% in the fourth quarter. Perritt Capital Management Inc now owns 190,000 shares of the company’s stock valued at $144,000 after acquiring an additional 107,068 shares in the last quarter. Finally, Sheets Smith Wealth Management acquired a new position in shares of ProPhase Labs in the fourth quarter valued at approximately $158,000. Hedge funds and other institutional investors own 9.45% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com started coverage on ProPhase Labs in a research report on Tuesday, February 25th. They set a “sell” rating on the stock.

ProPhase Labs Trading Down 8.2 %

Shares of PRPH opened at $0.27 on Wednesday. ProPhase Labs, Inc. has a twelve month low of $0.22 and a twelve month high of $5.55. The firm has a market capitalization of $11.33 million, a P/E ratio of -0.21 and a beta of -0.47. The company has a current ratio of 1.47, a quick ratio of 1.33 and a debt-to-equity ratio of 0.48. The stock’s fifty day simple moving average is $0.36 and its 200 day simple moving average is $0.67.

About ProPhase Labs

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.